Proteome Sciences Plc Stock Fundamentals
| PMSNF Stock | USD 0.04 0.00 0.00% |
Fundamental analysis of Proteome Sciences allows traders to better anticipate movements in Proteome Sciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Proteome |
Proteome Sciences plc Company Return On Asset Analysis
Proteome Sciences' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Proteome Sciences Return On Asset | 0.06 |
Most of Proteome Sciences' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Proteome Sciences plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Proteome Sciences plc has a Return On Asset of 0.06. This is 100.69% lower than that of the Healthcare sector and 100.8% lower than that of the Diagnostics & Research industry. The return on asset for all United States stocks is 142.86% lower than that of the firm.
Proteome Sciences plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Proteome Sciences's current stock value. Our valuation model uses many indicators to compare Proteome Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Proteome Sciences competition to find correlations between indicators driving Proteome Sciences's intrinsic value. More Info.Proteome Sciences plc is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in profit margin category among its peers fabricating about 1.46 of Profit Margin per Return On Asset. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Proteome Sciences' earnings, one of the primary drivers of an investment's value.Proteome Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Proteome Sciences' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Proteome Sciences could also be used in its relative valuation, which is a method of valuing Proteome Sciences by comparing valuation metrics of similar companies.Proteome Sciences is currently under evaluation in return on asset category among its peers.
Proteome Fundamentals
| Return On Asset | 0.06 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 25.13 M | |||
| Shares Outstanding | 295.18 M | |||
| Shares Owned By Insiders | 21.49 % | |||
| Shares Owned By Institutions | 22.89 % | |||
| Price To Earning | 50.00 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 5.13 M | |||
| Gross Profit | 2.96 M | |||
| EBITDA | 625 K | |||
| Net Income | 72 K | |||
| Cash And Equivalents | 3.2 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 11.68 M | |||
| Current Ratio | 0.45 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | 793 K | |||
| Number Of Employees | 27 | |||
| Beta | 0.0015 | |||
| Market Capitalization | 14.76 M | |||
| Total Asset | 10.04 M | |||
| Retained Earnings | (68 M) | |||
| Working Capital | (7 M) | |||
| Current Asset | 2 M | |||
| Current Liabilities | 9 M | |||
| Z Score | -7.8 | |||
| Net Asset | 10.04 M |
About Proteome Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Proteome Sciences plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Proteome Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Proteome Sciences plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company was incorporated in 1993 and is based in Cobham, the United Kingdom. Proteome Sciences operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Proteome Pink Sheet
Proteome Sciences financial ratios help investors to determine whether Proteome Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Proteome with respect to the benefits of owning Proteome Sciences security.